Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + Paclitaxel in NSCLC (LUX-Lung 5)
NCT01085136Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of afatinib in non-small cell lung carcinoma (NSCLC), sponsored by Boehringer Ingelheim. Started Feb 2010; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT01085136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085136.